Neogenomics Inc. Presents at UBS Global Healthcare Conference, May-21-2013 01:00 PM. Venue: Sheraton New York Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: Steven C. Jones, Chief Compliance Officer, Executive Vice President of Finance, Director and Chairman of Compliance Committee.

Neogenomics Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported revenue of $15,657,000 against $15,160,000 for the same period in the last year. Income from operations was $305,000 against $861,000 for the same period in the last year. Income before income taxes was $20,000 against $603,000 for the same period in the last year. Net income was $3,000 or $0.00 per share against $603,000 or $0.01 per share for the same period in the last year. Net cash used in operating activities was $1,330,000 against $1,065,000 for the same period in the last year. EBITDA was $1,350,000 against $1,624,000 for the same period in the last year. Adjusted EBITDA was $1,794,000 against $1,775,000 for the same period in the last year. Adjusted EBITDA for the 2013 first quarter was largely unchanged from last year's first quarter as a result of the $1.3 million reduction in quarterly revenues from the TCGF expiration and higher depreciation and stock-based compensation expense. Revenue for the 2013 first quarter increased 3% over first quarter 2012 on test volume growth of 19%. The company provided earnings guidance for the second quarter and full year of 2013. In second quarter, the company expects revenue of $15.8 - $16.4 million and net income of $0.00 to $0.01 per share. This guidance is based on organic growth in the current business, and the company reserves the right to adjust this guidance at any time based on the ongoing execution of its business plan. The company expects to maintain approximately 46% gross margins. The company for the full year expects revenue at $68 million to $73 million, with net income of $0.03 to $0.05 per share.

On April 22, 2013, the board of directors of Neogenomics Inc. appointed Mr. Steven A. Ross to serve as Chief Information Officer of the company until his successor is duly appointed, qualified and seated or until his earlier resignation or removal. Mr. Ross, will be responsible for the overall management of the company's information systems and information technology infrastructure. Prior to joining the company, Mr. Ross served as Vice President Technology at Chico's FAS Inc.